Exact Mass: 293.1562

Exact Mass Matches: 293.1562

Found 119 metabolites which its exact mass value is equals to given mass value 293.1562, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Ondansetron

9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one

C18H19N3O (293.1528)


Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. [HMDB] Ondansetron is a well tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drugs use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system; Ondansetron is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors; A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties; Ondansetron (INN) is a serotonin 5-HT3 receptor antagonist used mainly to treat nausea and vomiting following chemotherapy. Its effects are thought to be on both peripheral and central nerves. One part is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata, the other is a blockage of serotonin receptors in the chemoreceptor trigger zone. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D003879 - Dermatologic Agents > D000982 - Antipruritics CONFIDENCE standard compound; INTERNAL_ID 2746 CONFIDENCE standard compound; INTERNAL_ID 8525 D002491 - Central Nervous System Agents Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity[1][2][3][4][5][6][7][8].

   

Anastrozole

alpha,alpha,Alpha,alpha-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile

C17H19N5 (293.164)


Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens. CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7616; ORIGINAL_PRECURSOR_SCAN_NO 7613 CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7651; ORIGINAL_PRECURSOR_SCAN_NO 7649 CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7606; ORIGINAL_PRECURSOR_SCAN_NO 7604 CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7609; ORIGINAL_PRECURSOR_SCAN_NO 7607 CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7592; ORIGINAL_PRECURSOR_SCAN_NO 7590 CONFIDENCE standard compound; INTERNAL_ID 166; DATASET 20200303_ENTACT_RP_MIX500; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7638; ORIGINAL_PRECURSOR_SCAN_NO 7636 L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BG - Aromatase inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D047072 - Aromatase Inhibitors C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist CONFIDENCE standard compound; INTERNAL_ID 2750 CONFIDENCE standard compound; INTERNAL_ID 8532 D000970 - Antineoplastic Agents

   

N-Fructosyl isoleucine

(2S)-3-methyl-2-({[(3S,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl}amino)pentanoic acid

C12H23NO7 (293.1474)


Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)isoleucine is classified as a Natural Food Constituent (code WA) in the DFC.

   

N-(1-Deoxy-1-fructosyl)leucine

(2S)-4-methyl-2-({[(3S,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl}amino)pentanoic acid

C12H23NO7 (293.1474)


Fructose aminoacids are naturally occurring compounds derived from D-fructose and L-aminoacids. They are amadori products resulting from sugar-aminoacid interactions in food products, especially cooked foods [CCD] N-(1-Deoxy-1-fructosyl)leucine is classified as a Natural Food Constituent (code WA) in the DFC.

   

3,4,5-Trihydroxypentanoylcarnitine

3-[(3,4,5-trihydroxypentanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO7 (293.1474)


3,4,5-trihydroxypentanoylcarnitine is an acylcarnitine. More specifically, it is an 3,4,5-trihydroxypentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4,5-trihydroxypentanoylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 3,4,5-trihydroxypentanoylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Acridine carboxamide

N-[2-(Dimethylamino)ethyl]acridine-4-carboximidate

C18H19N3O (293.1528)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors

   

4-(2-hydroxy-5,7-dimethyl-4-oxo6,8-nonadienyl)-2,6-piperidinedione

4-(2-hydroxy-5,7-dimethyl-4-oxo6,8-nonadienyl)-2,6-piperidinedione

C16H23NO4 (293.1627)


   

11-Hydroxy-6-methyl-5,3a-(iminopropano)spiro[tetrahydrofuran-2,3-hydrindane]-2,4-dione

11-Hydroxy-6-methyl-5,3a-(iminopropano)spiro[tetrahydrofuran-2,3-hydrindane]-2,4-dione

C16H23NO4 (293.1627)


   
   

lannotinidine E

lannotinidine E

C16H23NO4 (293.1627)


   

3-Hydroxy-2-oxodendrobine

3-Hydroxy-2-oxodendrobine

C16H23NO4 (293.1627)


   

AKOS034145070

AKOS034145070

C16H23NO4 (293.1627)


   

(2E,7E,9E)-N-(2-hydroxy-2-methylpropyl)-6,11-dioxo-2,7,9-dodecatrienamide

(2E,7E,9E)-N-(2-hydroxy-2-methylpropyl)-6,11-dioxo-2,7,9-dodecatrienamide

C16H23NO4 (293.1627)


   

N,N-di(methoxycarbonylethyl)-2,6-dimethylaniline

N,N-di(methoxycarbonylethyl)-2,6-dimethylaniline

C16H23NO4 (293.1627)


   
   

N-[2-(1H-indol-3-yl)ethyl]-2-(methylamino)benzamide

N-[2-(1H-indol-3-yl)ethyl]-2-(methylamino)benzamide

C18H19N3O (293.1528)


   

a jasmonoyl-1-aminocyclopropane-1 carboxylate

a jasmonoyl-1-aminocyclopropane-1 carboxylate

C16H23NO4 (293.1627)


   

Anastrozole

Anastrozole

C17H19N5 (293.164)


L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BG - Aromatase inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D065088 - Steroid Synthesis Inhibitors D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D004965 - Estrogen Antagonists C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D004791 - Enzyme Inhibitors > D065088 - Steroid Synthesis Inhibitors > D047072 - Aromatase Inhibitors C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1740 - Aromatase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist D000970 - Antineoplastic Agents

   

ondansetron

Ondansetron aka "9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one"

C18H19N3O (293.1528)


A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D003879 - Dermatologic Agents > D000982 - Antipruritics D002491 - Central Nervous System Agents Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist, with IC50 value of 103 pM. Ondansetron exerts antiemetic effects by antagonizing 5-HT receptor located on local neurons in the peripheral and central nervous system. Ondansetron suppresses nausea and vomiting caused by chemotherapy and radiation therapy. Ondansetron has orally bioactivity[1][2][3][4][5][6][7][8].

   

3,4,5,6-tetradehydrogeissoschizol

3,4,5,6-tetradehydrogeissoschizol

[C19H21N2O]+ (293.1654)


   

N-Fructosyl isoleucine

N-Fructosyl isoleucine

C12H23NO7 (293.1474)


Annotation level-3

   

Fabesetron

Fabesetron

C18H19N3O (293.1528)


C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3660; ORIGINAL_PRECURSOR_SCAN_NO 3659 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3638; ORIGINAL_PRECURSOR_SCAN_NO 3636 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3651; ORIGINAL_PRECURSOR_SCAN_NO 3649 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3679; ORIGINAL_PRECURSOR_SCAN_NO 3675 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3688; ORIGINAL_PRECURSOR_SCAN_NO 3687 DATASET 20200303_ENTACT_RP_MIX505; CONFIDENCE standard compound; INTERNAL_ID 393; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3974; ORIGINAL_PRECURSOR_SCAN_NO 3970 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3974; ORIGINAL_PRECURSOR_SCAN_NO 3970 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8035; ORIGINAL_PRECURSOR_SCAN_NO 8033 INTERNAL_ID 393; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8035; ORIGINAL_PRECURSOR_SCAN_NO 8033 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8049; ORIGINAL_PRECURSOR_SCAN_NO 8045 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8030; ORIGINAL_PRECURSOR_SCAN_NO 8029 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8041; ORIGINAL_PRECURSOR_SCAN_NO 8036 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8063; ORIGINAL_PRECURSOR_SCAN_NO 8062 CONFIDENCE standard compound; INTERNAL_ID 393; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7948; ORIGINAL_PRECURSOR_SCAN_NO 7944

   

9H-Carbazole-3-boronic acid pinacol ester

9H-Carbazole-3-boronic acid pinacol ester

C18H20BNO2 (293.1587)


   
   

2-(2-AMINOPHENYL)-5-(4-(TERT-BUTYL)PHENYL)-1,3,4-OXADIAZOLE

2-(2-AMINOPHENYL)-5-(4-(TERT-BUTYL)PHENYL)-1,3,4-OXADIAZOLE

C18H19N3O (293.1528)


   

(3S,4S)-TERT-BUTYL 3-HYDROXY-4-(4-HYDROXYPHENYL)PIPERIDINE-1-CARBOXYLATE

(3S,4S)-TERT-BUTYL 3-HYDROXY-4-(4-HYDROXYPHENYL)PIPERIDINE-1-CARBOXYLATE

C16H23NO4 (293.1627)


   

3,5-Dip-tolyl-4,5-dihydro-1H-pyrazole-1-carboxamide

3,5-Dip-tolyl-4,5-dihydro-1H-pyrazole-1-carboxamide

C18H19N3O (293.1528)


   

(S)-(3B,12B)-12,20-DIHYDROXYDAMMAR-24-EN-3-YLBETA-D-GLUCOPYRANOSIDE

(S)-(3B,12B)-12,20-DIHYDROXYDAMMAR-24-EN-3-YLBETA-D-GLUCOPYRANOSIDE

C16H23NO4 (293.1627)


   

CHEMBRDG-BB 4011737

CHEMBRDG-BB 4011737

C16H23NO4 (293.1627)


   

Ethyl [3-(triethoxysilyl)propyl]carbamate

Ethyl [3-(triethoxysilyl)propyl]carbamate

C12H27NO5Si (293.1658)


   

dimazole

Diamthazole

C15H23N3OS (293.1562)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

(S)-2-((tert-Butoxycarbonyl)amino)-5-phenylpentanoic acid

(S)-2-((tert-Butoxycarbonyl)amino)-5-phenylpentanoic acid

C16H23NO4 (293.1627)


   

boc-d-2-amino-5-phenyl-pentanoic acid dcha salt

boc-d-2-amino-5-phenyl-pentanoic acid dcha salt

C16H23NO4 (293.1627)


   

2-N-BOC-2-AMINOMETHYL-3-M-TOLYL-PROPIONIC ACID

2-N-BOC-2-AMINOMETHYL-3-M-TOLYL-PROPIONIC ACID

C16H23NO4 (293.1627)


   

2-N-BOC-2-AMINOMETHYL-3-P-TOLYL-PROPIONIC ACID

2-N-BOC-2-AMINOMETHYL-3-P-TOLYL-PROPIONIC ACID

C16H23NO4 (293.1627)


   

azane,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,furan-2,5-dione,oxirane

azane,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,furan-2,5-dione,oxirane

C12H23NO7 (293.1474)


   

(R)-4-((TERT-BUTOXYCARBONYL)AMINO)-5-PHENYLPENTANOIC ACID

(R)-4-((TERT-BUTOXYCARBONYL)AMINO)-5-PHENYLPENTANOIC ACID

C16H23NO4 (293.1627)


   

Boc-L-2,4-dimethylphe

Boc-L-2,4-dimethylphe

C16H23NO4 (293.1627)


   

Boc-D-2,4-dimethylphe

Boc-D-2,4-dimethylphe

C16H23NO4 (293.1627)


   

methyl (E)-3-[2-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]prop-2-enoate

methyl (E)-3-[2-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]prop-2-enoate

C16H23NO4 (293.1627)


   

tert-butyl-dimethyl-(1-methylsulfonylpiperidin-4-yl)oxysilane

tert-butyl-dimethyl-(1-methylsulfonylpiperidin-4-yl)oxysilane

C12H27NO3SSi (293.1481)


   

Boc-(R)-3-Amino-4-(4-methylphenyl)-butyric acid

Boc-(R)-3-Amino-4-(4-methylphenyl)-butyric acid

C16H23NO4 (293.1627)


   

5-AMINO-DI-T-BUTYL ISOPHTHALATE

5-AMINO-DI-T-BUTYL ISOPHTHALATE

C16H23NO4 (293.1627)


   

4-FLUORO-2-METHOXYPHENYLBORONICACID

4-FLUORO-2-METHOXYPHENYLBORONICACID

C16H23NO4 (293.1627)


   

Streptimidone

Streptimidone

C16H23NO4 (293.1627)


   

9H-Carbazole-2-boronic acid pinacol ester

9H-Carbazole-2-boronic acid pinacol ester

C18H20BNO2 (293.1587)


   

Boc-(R)-3-amino-4-(2-methylphenyl)-butyric acid

Boc-(R)-3-amino-4-(2-methylphenyl)-butyric acid

C16H23NO4 (293.1627)


   

Boc-(S)-3-Amino-4-(3-methyl-phenyl)-butyric acid

Boc-(S)-3-Amino-4-(3-methyl-phenyl)-butyric acid

C16H23NO4 (293.1627)


   

Boc-(S)-3-Amino-4-(4-methyl-phenyl)-butyric acid

Boc-(S)-3-Amino-4-(4-methyl-phenyl)-butyric acid

C16H23NO4 (293.1627)


   

Boc-(S)-3-Amino-5-phenylpentanoic acid

Boc-(S)-3-Amino-5-phenylpentanoic acid

C16H23NO4 (293.1627)


   

BENZYL ((S)-1-HYDROXY-3-((R)-TETRAHYDRO-2H-PYRAN-3-YL)PROPAN-2-YL)CARBAMATE

BENZYL ((S)-1-HYDROXY-3-((R)-TETRAHYDRO-2H-PYRAN-3-YL)PROPAN-2-YL)CARBAMATE

C16H23NO4 (293.1627)


   

BETA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENEBUTANOIC ACID METHYL ESTER

BETA-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-BENZENEBUTANOIC ACID METHYL ESTER

C16H23NO4 (293.1627)


   

CIS-STILBENEBORONIC ACID DIETHANOLAMINE ESTER

CIS-STILBENEBORONIC ACID DIETHANOLAMINE ESTER

C18H20BNO2 (293.1587)


   

4-Nitrophenyl decanoate

4-Nitrophenyl decanoate

C16H23NO4 (293.1627)


   

L-Lysine L-glutamate

L-Lysine L-glutamate

C11H23N3O6 (293.1587)


   

1-BENZYL-2,3-DIMETHYL-1H-INDOLE-5-CARBOHYDRAZIDE

1-BENZYL-2,3-DIMETHYL-1H-INDOLE-5-CARBOHYDRAZIDE

C18H19N3O (293.1528)


   

promolate

promolate

C16H23NO4 (293.1627)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

2-PYRIDIN-2-YLMALONIC ACID DI-TERT-BUTYL ESTER

2-PYRIDIN-2-YLMALONIC ACID DI-TERT-BUTYL ESTER

C16H23NO4 (293.1627)


   

6-(4-ISOPROPOXY-BENZOYLAMINO)-HEXANOIC ACID

6-(4-ISOPROPOXY-BENZOYLAMINO)-HEXANOIC ACID

C16H23NO4 (293.1627)


   

α,α-Bis[2-(diMethylaMino)ethyl]-

α,α-Bis[2-(diMethylaMino)ethyl]-

C16H24ClN3 (293.1659)


   

Boc-(R)-3-Amino-5-phenylpentanoic acid

Boc-(R)-3-Amino-5-phenylpentanoic acid

C16H23NO4 (293.1627)


   

ABT-724

2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole

C17H19N5 (293.164)


   

di-n-butyl 4-aminophthalate

di-n-butyl 4-aminophthalate

C16H23NO4 (293.1627)


   

1-[1-[(4-Chlorophenyl)Methyl]-4-piperidinyl] piperazine

1-[1-[(4-Chlorophenyl)Methyl]-4-piperidinyl] piperazine

C16H24ClN3 (293.1659)


   

methyl5,5-dimethoxy-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carboxylate

methyl5,5-dimethoxy-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carboxylate

C16H23NO4 (293.1627)


   

METHYL 4-[N-BENZYL-N-(2-ETHOXY-2-OXOETHYL)AMINO]BUTANOATE

METHYL 4-[N-BENZYL-N-(2-ETHOXY-2-OXOETHYL)AMINO]BUTANOATE

C16H23NO4 (293.1627)


   

Boc-(S)-3-Amino-4-(2-methyl-phenyl)-butyric acid

Boc-(S)-3-Amino-4-(2-methyl-phenyl)-butyric acid

C16H23NO4 (293.1627)


   

1-((5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)THIOPHEN-2-YL)METHYL)PYRROLIDINE

1-((5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)THIOPHEN-2-YL)METHYL)PYRROLIDINE

C15H24BNO2S (293.1621)


   

(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride

(R)-tert-Butyl 2-(dimethylcarbamoyl)piperazine-1-carboxylate hydrochloride

C12H24ClN3O3 (293.1506)


   

BENZENEPROPANOIC ACID,-[2-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]ETHYL]-

BENZENEPROPANOIC ACID,-[2-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]ETHYL]-

C16H23NO4 (293.1627)


   

Boc-(R)-3-Amino-4-(3-methyl-phenyl)-butyric acid

Boc-(R)-3-Amino-4-(3-methyl-phenyl)-butyric acid

C16H23NO4 (293.1627)


   
   

Jasmonic acid/1-amino-1-cyclopropane carboxylic acid

Jasmonic acid/1-amino-1-cyclopropane carboxylic acid

C16H23NO4 (293.1627)


   

3-[(6-Methyl-4-phenyl-2-quinazolinyl)amino]-1-propanol

3-[(6-Methyl-4-phenyl-2-quinazolinyl)amino]-1-propanol

C18H19N3O (293.1528)


   

1-[(4-Methylphenyl)methyl]-4-(1-pyrrolidinyl)pyrazolo[3,4-d]pyrimidine

1-[(4-Methylphenyl)methyl]-4-(1-pyrrolidinyl)pyrazolo[3,4-d]pyrimidine

C17H19N5 (293.164)


   

3-Methyl-2-[[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methylamino]pentanoic acid

3-Methyl-2-[[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methylamino]pentanoic acid

C12H23NO7 (293.1474)


   

salinosporamide E

salinosporamide E

C16H23NO4 (293.1627)


   
   

4-Coumaroyl-3-hydroxyagmatine

4-Coumaroyl-3-hydroxyagmatine

C14H21N4O3+ (293.1614)


   

3,4,5-Trihydroxypentanoylcarnitine

3,4,5-Trihydroxypentanoylcarnitine

C12H23NO7 (293.1474)


   

3-(1-Benzylpiperidin-4-yl)triazolo[4,5-b]pyridine

3-(1-Benzylpiperidin-4-yl)triazolo[4,5-b]pyridine

C17H19N5 (293.164)


   

1-(4-Butylphenyl)-3-(4-morpholinyl)thiourea

1-(4-Butylphenyl)-3-(4-morpholinyl)thiourea

C15H23N3OS (293.1562)


   

Fructosyl leucine

Fructosyl leucine

C12H23NO7 (293.1474)


   

Sieboldine A(rel)

Sieboldine A(rel)

C16H23NO4 (293.1627)


A natural product found in Lycopodium sieboldii.

   

Fructosyl isoleucine

Fructosyl isoleucine

C12H23NO7 (293.1474)


   

N(alpha)-acetyl-L-histidyl-D-prolinamide

N(alpha)-acetyl-L-histidyl-D-prolinamide

C13H19N5O3 (293.1488)


   

2-[(3E)-3-ethylidene-1,2,4,12-tetrahydroindolo[2,3-a]quinolizin-5-ium-2-yl]ethanol

2-[(3E)-3-ethylidene-1,2,4,12-tetrahydroindolo[2,3-a]quinolizin-5-ium-2-yl]ethanol

C19H21N2O+ (293.1654)


   

methyl 4,6-dideoxy-4-[(2S)-2,4-dihydroxybutanamido]-2-O-methyl-alpha-D-mannopyranoside

methyl 4,6-dideoxy-4-[(2S)-2,4-dihydroxybutanamido]-2-O-methyl-alpha-D-mannopyranoside

C12H23NO7 (293.1474)


   

trimethyl-[(1R,9S)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaen-13-yl]silane

trimethyl-[(1R,9S)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaen-13-yl]silane

C19H23NSi (293.16)


   

trimethyl-[(1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaen-13-yl]silane

trimethyl-[(1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaen-13-yl]silane

C19H23NSi (293.16)


   

N-Methyl-N-bis(trimethylsilyl)methylbenzamide

N-Methyl-N-bis(trimethylsilyl)methylbenzamide

C15H27NOSi2 (293.1631)


   

2,2-Dimethyl-3-[[[(1-phenylethyl)amino]carbonyl]oxy]propionic acid ethyl ester

2,2-Dimethyl-3-[[[(1-phenylethyl)amino]carbonyl]oxy]propionic acid ethyl ester

C16H23NO4 (293.1627)


   

N-(1-Deoxy-1-fructosyl)leucine

N-(1-Deoxy-1-fructosyl)leucine

C12H23NO7 (293.1474)


   

N-(1-Deoxy-1-fructosyl)isoleucine

N-(1-Deoxy-1-fructosyl)isoleucine

C12H23NO7 (293.1474)


   

NA-Taurine 11:0

NA-Taurine 11:0

C13H27NO4S (293.1661)


   
   

Cyclo(Arg-His)

Cyclo(Arg-His)

C12H19N7O2 (293.16)


   

(+)-N-Allylnormetazocine (hydrochloride)

(+)-N-Allylnormetazocine (hydrochloride)

C17H24ClNO (293.1546)


(+)-N-Allylnormetazocine ((+)-SKF 10047) hydrochloride is a benzomorphan opioid with psychotomi metic effects. (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist with Ki values of 300 nM and 27 μM for σ1 and σ2 opioid receptors, respectively. (+)-N-Allylnormetazocine hydrochloride can be used for the research of neurological disease[1][2].

   

3-hydroxy-2-oxodendrobine

NA

C16H23NO4 (293.1627)


{"Ingredient_id": "HBIN008646","Ingredient_name": "3-hydroxy-2-oxodendrobine","Alias": "NA","Ingredient_formula": "C16H23NO4","Ingredient_Smile": "NA","Ingredient_weight": "293.36","OB_score": "NA","CAS_id": "99616-00-9","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8095","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1r,4r,5s)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-3-hydroxy-5-methyl-4-propyl-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one

(1r,4r,5s)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-3-hydroxy-5-methyl-4-propyl-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one

C16H23NO4 (293.1627)


   

(5z)-1-acetyl-5-ethylidene-4-hydroxy-3-octanoylpyrrol-2-one

(5z)-1-acetyl-5-ethylidene-4-hydroxy-3-octanoylpyrrol-2-one

C16H23NO4 (293.1627)


   

2,3-dihydroxy-14-methyl-11-oxa-5-azapentacyclo[7.4.3.1¹⁰,¹³.0¹,¹⁶.0⁵,¹⁶]heptadecan-12-one

2,3-dihydroxy-14-methyl-11-oxa-5-azapentacyclo[7.4.3.1¹⁰,¹³.0¹,¹⁶.0⁵,¹⁶]heptadecan-12-one

C16H23NO4 (293.1627)


   

(5e,8r,9e)-3-(c-hydroxycarbonimidoylmethyl)-8,10-dimethyl-7-oxododeca-5,9,11-trienoic acid

(5e,8r,9e)-3-(c-hydroxycarbonimidoylmethyl)-8,10-dimethyl-7-oxododeca-5,9,11-trienoic acid

C16H23NO4 (293.1627)


   

13-hydroxy-6-methyl-17-oxa-13-azatetracyclo[12.2.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

13-hydroxy-6-methyl-17-oxa-13-azatetracyclo[12.2.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

C16H23NO4 (293.1627)


   

(2e,7e,9e)-n-(2-hydroxy-2-methylpropyl)-6,11-dioxododeca-2,7,9-trienimidic acid

(2e,7e,9e)-n-(2-hydroxy-2-methylpropyl)-6,11-dioxododeca-2,7,9-trienimidic acid

C16H23NO4 (293.1627)


   

6-hydroxy-4-[(2r,5s,6e)-2-hydroxy-5,7-dimethyl-4-oxonona-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-[(2r,5s,6e)-2-hydroxy-5,7-dimethyl-4-oxonona-6,8-dien-1-yl]-4,5-dihydro-3h-pyridin-2-one

C16H23NO4 (293.1627)


   

methyl 2-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]acetate

methyl 2-[(2s)-1-{4-[(2e)-4-methyl-5-oxofuran-2-ylidene]butyl}pyrrolidin-2-yl]acetate

C16H23NO4 (293.1627)


   

(2e)-5-[(6s)-5-(hydroxymethyl)-6-methyl-4-oxatricyclo[3.3.1.0²,⁷]nonan-2-yl]-2-methyl-4-oxopent-2-enimidic acid

(2e)-5-[(6s)-5-(hydroxymethyl)-6-methyl-4-oxatricyclo[3.3.1.0²,⁷]nonan-2-yl]-2-methyl-4-oxopent-2-enimidic acid

C16H23NO4 (293.1627)


   

n-(2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enimidic acid

n-(2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enimidic acid

C16H23NO4 (293.1627)


   

methyl 2-{1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl}acetate

methyl 2-{1-[4-(4-methyl-5-oxofuran-2-ylidene)butyl]pyrrolidin-2-yl}acetate

C16H23NO4 (293.1627)


   

(1r,2s,3s,9s,10r,13s,14r,16s)-2,3-dihydroxy-14-methyl-11-oxa-5-azapentacyclo[7.4.3.1¹⁰,¹³.0¹,¹⁶.0⁵,¹⁶]heptadecan-12-one

(1r,2s,3s,9s,10r,13s,14r,16s)-2,3-dihydroxy-14-methyl-11-oxa-5-azapentacyclo[7.4.3.1¹⁰,¹³.0¹,¹⁶.0⁵,¹⁶]heptadecan-12-one

C16H23NO4 (293.1627)


   

(1r,4s,6r,9s,14s)-13-hydroxy-6-methyl-17-oxa-13-azatetracyclo[12.2.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

(1r,4s,6r,9s,14s)-13-hydroxy-6-methyl-17-oxa-13-azatetracyclo[12.2.1.0¹,⁹.0⁴,⁹]heptadecane-2,8-dione

C16H23NO4 (293.1627)


   

1-[cyclohex-2-en-1-yl(hydroxy)methyl]-3-hydroxy-5-methyl-4-propyl-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one

1-[cyclohex-2-en-1-yl(hydroxy)methyl]-3-hydroxy-5-methyl-4-propyl-6-oxa-2-azabicyclo[3.2.0]hept-2-en-7-one

C16H23NO4 (293.1627)


   

6-hydroxy-4-(2-hydroxy-5,7-dimethyl-4-oxonona-6,8-dien-1-yl)-4,5-dihydro-3h-pyridin-2-one

6-hydroxy-4-(2-hydroxy-5,7-dimethyl-4-oxonona-6,8-dien-1-yl)-4,5-dihydro-3h-pyridin-2-one

C16H23NO4 (293.1627)


   

5-[5-(hydroxymethyl)-6-methyl-4-oxatricyclo[3.3.1.0²,⁷]nonan-2-yl]-2-methyl-4-oxopent-2-enimidic acid

5-[5-(hydroxymethyl)-6-methyl-4-oxatricyclo[3.3.1.0²,⁷]nonan-2-yl]-2-methyl-4-oxopent-2-enimidic acid

C16H23NO4 (293.1627)


   

({4-methoxy-1h,1'h-[2,2'-bipyrrol]-5-yl}methylidene)(2-phenylethyl)amine

({4-methoxy-1h,1'h-[2,2'-bipyrrol]-5-yl}methylidene)(2-phenylethyl)amine

C18H19N3O (293.1528)


   

(2e)-n-(2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enimidic acid

(2e)-n-(2-methylpropyl)-3-(3,4,5-trimethoxyphenyl)prop-2-enimidic acid

C16H23NO4 (293.1627)


   

1-acetyl-5-ethylidene-4-hydroxy-3-octanoylpyrrol-2-one

1-acetyl-5-ethylidene-4-hydroxy-3-octanoylpyrrol-2-one

C16H23NO4 (293.1627)